BRCA1 and BRCA2 deficient tumor cells are sensitive to inhibitors of Poly ADP Ribose
Polymerase (PARP1) through the mechanism of synthetic lethality. Several PARP inhibitors,
which are oral drugs and generally well tolerated, have now received FDA approval for
various ovarian cancer and breast cancer indications. Despite their use in the clinic, PARP
inhibitor resistance is common and develops through multiple mechanisms. Broadly
speaking, BRCA1/2-deficient tumor cells can become resistant to PARP inhibitors by …